IVERIC bio Inc
Change company Symbol lookup
Select an option...
OXY Occidental Petroleum Corp
LGACW Lazard Growth Acquisition I Warrants Exp 10 Feb 2026 *W EXP 02/10/2026
EYPT EyePoint Pharmaceuticals Inc
EML Eastern Co
FERG Ferguson PLC
PDCO Patterson Companies Inc
ESE ESCO Technologies Inc
GNUS Genius Brands International Inc
BMAC+ Black Mountain Acquisition Equity Warrants Exp 15th Oct 2027 *W EXP 11/15/2027

Health Care : Biotechnology | Small Cap Growth
Company profile

IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development ofl treatments for retinal diseases with unmet medical needs. Its lead asset clinical stage product candidate Zimura, a complement C5 inhibitor. Zimura is targeting diseases include: Geographic Atrophy (GA), intermediate (age-related macular degeneration) AMD, and autosomal recessive Stargardt disease (STGD1). It is also developing preclinical product candidate IC-500, a High temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA and potentially other age-related retinal diseases. Its portfolio also includes two preclinical stage gene therapy product candidates, which include IC-100 and IC-200 and several ongoing gene therapy research programs. The Company is developing IC-100 for rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) and IC-200 for bestrophin-1 (BEST1) related IRDs.

Closing Price
Day's Change
0.47 (4.71%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Cameco Announces Election of Directors

5:03 pm ET May 10, 2022 (BusinessWire) Print

Cameco (TSX: CCO; NYSE: CCJ) has announced the election of nine board members at its annual meeting held on May 10, 2022.

Shareholders elected board members Leontine Atkins, Ian Bruce, Daniel Camus, Donald Deranger, Catherine Gignac, Tim Gitzel, Jim Gowans, Kathryn Jackson and Don Kayne.

Voting Results for Cameco Directors

Nominee           Votes For  % Votes For Withheld % Votes Withheld
---------------- ---------- ----------- --------- ----------------
Leontine Atkins  34,045,964    97.26%     958,868       2.74%
---------------- ---------- ----------- --------- ----------------
Ian Bruce        33,809,315    96.58%    1,195,517      3.42%
---------------- ---------- ----------- --------- ----------------
Daniel Camus     32,814,657    93.74%    2,190,175      6.26%
---------------- ---------- ----------- --------- ----------------
Donald Deranger  33,389,776    95.39%    1,615,056      4.61%
---------------- ---------- ----------- --------- ----------------
Catherine Gignac 33,758,357    96.44%    1,246,475      3.56%
---------------- ---------- ----------- --------- ----------------
Tim Gitzel       34,679,038    99.07%     325,794       0.93%
---------------- ---------- ----------- --------- ----------------
Jim Gowans       31,004,171    88.57%    4,000,661     11.43%
---------------- ---------- ----------- --------- ----------------
Kathryn Jackson  34,488,853    98.53%     515,979       1.47%
---------------- ---------- ----------- --------- ----------------


Cameco is one of the largest global providers of the uranium fuel needed to energize a clean-air world. Our competitive position is based on our controlling ownership of the world's largest high-grade reserves and low-cost operations. Utilities around the world rely on our nuclear fuel products to generate power in safe, reliable, carbon-free nuclear reactors. Our shares trade on the Toronto and New York stock exchanges. Our head office is in Saskatoon, Saskatchewan.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220510006450/en/

SOURCE: Cameco">

Investor inquiries: 
Rachelle Girard

Media inquiries: 
Jeff Hryhoriw
comtex tracking


Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.